Becton, Dickinson and Co. news

   Watch this stock
Showing stories 1 - 10 of about 103   

Articles published

BDX 112.85 -0.91 (-0.80%)
price chart
Becton Dickinson & Co. Price Target Raised to $130.00 at ISI Group (BDX)
Becton Dickinson & Co. logo ISI Group increased their target price on shares of Becton Dickinson & Co. (NYSE:BDX) from $123.00 to $130.00 in a research note issued on Monday, StockRatingsNetwork.com reports. The firm currently has a �buy� rating on the ...
Becton Dickinson & Co. Given New $130.00 Price Target at ISI Group (BDX)  Ticker Report
Becton Dickinson & Co. Given Average Recommendation of "Hold" ...  Mideast Time
Related articles »  
Becton, Dickinson and Company (BDX): New Analyst Report from Zacks Equity ...
We reiterate our Neutral recommendation for Becton, Dickinson. Both earnings and revenues for the fiscal 2014 first quarter beat the Zacks Consensus Estimate by 10.1% ($0.13) and 12.8% ($36 million), respectively.
Related articles »  
Technical Roundup on Health Care Sector Stocks -- Research on Becton ...
Free technical research on BDX, ATRS, HH and CTRX can be downloaded upon signing up at: http://www.investor-edge.com/752-register Shares in Becton Dickinson and Co. registered a trading volume of 0.63 million shares, as compared with a three ...
Therasense, Inc.v. Becton, Dickinson & Co.
Procedural Posture: Defendants appealed the district court's denial of (1) appellate and remand fees and expenses; (2) fees spent seeking additional fees; (3) prejudgment interest on fees; and (4) post-judgment interest calculated from the date the ...
New Lifetime High Reached By Becton Dickinson (BDX)
TheStreet Quant Ratings rates Becton Dickinson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, good cash flow from operations and largely solid ...
Zacks Reiterates "Neutral" Rating for Becton Dickinson & Co. (BDX)
Becton Dickinson & Co. logo Zacks restated their neutral rating on shares of Becton Dickinson & Co. (NYSE:BDX) in a research note issued to investors on Wednesday, AnalystRatings.NET reports. The firm currently has a $120.00 price target on the stock.
Becton Dickinson & Co.'s "Neutral" Rating Reaffirmed at Zacks (BDX)
Becton Dickinson & Co. logo Becton Dickinson & Co. (NYSE:BDX)'s stock had its �neutral� rating restated by Zacks in a report released on Wednesday, Analyst Ratings Network.
Becton, Dickinson Gets CLIA-Waiver for RSV Test System - Analyst Blog
Medical technology major Becton, Dickinson and Company ( BDX ) revealed that it has received 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S.
Related articles »  
Becton, Dickinson Hits 52-Week High
Shares of Becton, Dickinson and Company (BDX - Analyst Report) reached a new 52-week high of $117.26 on Mar 31 eventually closing at $117.08 on the same day.
Related articles »  
Medical Instruments & Supplies: Antares Pharma (NASDAQ:ATRS), Covidien plc ...
Baxter International Inc. (NYSE:BAX) year to date performance is 6.23%. ISI Group increased their target price on shares of Becton Dickinson & Co. (NYSE:BDX) from $123.00 to $130.00 in a research note issued on Monday, StockRatingsNetwork.com reports ...